BeiGene Cash Flow from Operating Activities 2014-2024 | ONC
BeiGene annual/quarterly cash flow from operating activities history and growth rate from 2014 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
- BeiGene cash flow from operating activities for the quarter ending September 30, 2024 was $-0.216B, a 76.94% decline year-over-year.
- BeiGene cash flow from operating activities for the twelve months ending September 30, 2024 was $-2.086B, a 45.87% decline year-over-year.
- BeiGene annual cash flow from operating activities for 2023 was $-1.157B, a 22.66% decline from 2022.
- BeiGene annual cash flow from operating activities for 2022 was $-1.497B, a 15.24% increase from 2021.
- BeiGene annual cash flow from operating activities for 2021 was $-1.299B, a 1.19% increase from 2020.
BeiGene Annual Cash Flow Ops
(Millions of US $) |
| 2023 |
$-1,157 |
| 2022 |
$-1,497 |
| 2021 |
$-1,299 |
| 2020 |
$-1,283 |
| 2019 |
$-750 |
| 2018 |
$-548 |
| 2017 |
$13 |
| 2016 |
$-90 |
| 2015 |
$-40 |
| 2014 |
$-9 |
| 2013 |
$4 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
